Nasdaq
$377.00▼ 0.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $41.36BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 10.15After-hours26.10.16 06:084Ownership#●●●
BeOne Medicines Ltd.
Insider Wang Xiaodong of BeOne Medicines Ltd. reported a change in beneficial ownership of securities as of October 13, 2026. This filing is a standard Form 4 disclosure regarding insider stock transactions.…more
$377.00-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 05:534Ownership
BeOne Medicines Ltd.
Insider Lee Chan Henry has filed a Form 4 to report a change in beneficial ownership of securities for BeOne Medicines Ltd. as of September 30, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$377.00-0.21%vs prev closeView filingShare - 9.30After-hours26.10.01 06:114Ownership
BeOne Medicines Ltd.
Insider Wang Xiaodong reported a change in beneficial ownership of securities for BeOne Medicines Ltd. as of September 28, 2026. This filing serves as an official disclosure of the insider's equity transaction to the SEC.…more
$377.00-0.21%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:18#●●●#●●●#●●●
BeOne Medicines Confirms Phase 3 Efficacy for Gastric Cancer Treatment
BeOne Medicines announced positive Phase 3 clinical trial results confirming the benefits of its combination therapy for HER2-positive gastroesophageal adenocarcinoma. The findings are set to be presented at the ESMO Congress.…more
$377.00-0.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.31Regular26.09.01 04:07
●●●●●●●● ●●●●● ●●●●●●
BeOne Medicines has entered into a voluntary agreement with the U.S. government to improve patient access to cancer treatments and bolster its domestic manufacturing capabilities. The partnership underscores the company's commitment to research investment and scaling its drug delivery infrastructure.…more
$377.00-0.21%vs prev closeShareBenzinga - 8.31Pre-market26.08.31 19:09
●●●●●●●● ●●●●● ●●●●●●
BeOne Medicines announced that its Phase 3 HERIZON-GEA-01 trial met primary endpoints, showing statistically significant improvement in overall survival for HER2+ gastroesophageal adenocarcinoma patients. The results confirm the clinical efficacy and manageable safety profile of the ZIIHERA-based combination regimen.…more
$377.00-0.21%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report